Last updated: August 27, 2026
Nalfon is an oral fenoprofen calcium product used for rheumatoid arthritis and osteoarthritis. Its commercial opportunity is primarily in differentiated oral solid dosage forms, excipient modernization, supply-chain improvement, and 505(b)(2) reformulation strategies rather than biosimilar development. The core product has limited regulatory exclusivity leverage, so any investment case depends on measurable improvements in tolerability, adherence, manufacturability, or delivery.
What is Nalfon and which drug substance does it contain?
Nalfon contains fenoprofen calcium, a nonsteroidal anti-inflammatory drug in the propionic-acid class. The labeled strengths are 200 mg and 300 mg capsules in the U.S. market.[1]
| Attribute |
Nalfon |
| Active ingredient |
Fenoprofen calcium |
| Therapeutic class |
NSAID |
| Dosage form |
Immediate-release oral capsule |
| U.S. strengths |
200 mg and 300 mg |
| Primary indications |
Rheumatoid arthritis and osteoarthritis |
| Regulatory pathway |
Approved NDA product |
| Biosimilar relevance |
None; Nalfon is a small-molecule drug |
| Main competitive products |
Generic fenoprofen calcium capsules and other oral NSAIDs |
| Key commercial risks |
Low differentiation, NSAID class warnings, generic price pressure |
Fenoprofen calcium carries class risks associated with NSAIDs, including gastrointestinal bleeding, ulceration, cardiovascular thrombotic events, renal toxicity, and hypersensitivity reactions.[1] An excipient strategy cannot remove those pharmacologic risks, but it can improve product quality, dose uniformity, capsule performance, stability, and patient acceptability.
What excipients are used in Nalfon capsules?
The Nalfon label identifies inactive ingredients for the marketed capsule presentation. Public labeling indicates the use of conventional capsule excipients and capsule-shell components, including lactose, magnesium stearate, sodium lauryl sulfate, starch-related materials, gelatin, colorants, titanium dioxide, and other formulation aids depending on the strength and manufacturer.[1]
Because inactive ingredients can vary by strength, NDC, manufacturing site, and authorized generic source, product development should treat the current reference listed drug composition as a target profile rather than assume that every Nalfon capsule uses an identical excipient system.
Likely functional roles of the excipients
| Excipient category |
Formulation role |
Commercial relevance |
| Lactose or other diluent |
Provides capsule fill mass and improves powder handling |
Creates opportunities for lactose-free or low-lactose versions |
| Starch or disintegrant |
Supports capsule plug breakup and drug release |
Can be optimized for faster or more consistent dissolution |
| Magnesium stearate |
Lubrication during encapsulation |
Excess use can slow wetting and dissolution |
| Sodium lauryl sulfate |
Wetting and dispersion support |
May create tolerability or label-preference concerns |
| Colloidal silicon dioxide |
Flow improvement |
Supports high-speed capsule filling |
| Povidone or related binder |
Granule strength and content uniformity |
Useful if the formulation moves from direct fill to granulation |
| Gelatin capsule shell |
Standard hard-capsule delivery |
Creates opportunities for vegetarian or specialty shells |
| Titanium dioxide and colorants |
Appearance and product identification |
Relevant to consumer preferences and jurisdictional restrictions |
The strongest initial opportunity is not a novel excipient claim. It is a controlled reformulation that maintains equivalent exposure and dissolution while improving manufacturability, excipient acceptability, or capsule presentation.
What excipient strategies are technically suitable for fenoprofen calcium?
Lactose-free and low-allergen formulations
A lactose-free formulation could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, pregelatinized starch, or a combination of these materials. The choice depends on bulk density, flow, compressibility, moisture sensitivity, and capsule fill weight.
For a capsule product, microcrystalline cellulose and mannitol are commercially practical candidates. Mannitol can improve mouthfeel if the capsule is opened and sprinkled, while microcrystalline cellulose generally supports robust powder handling.
The principal development issue is that a diluent change can alter:
- Powder flow and capsule-fill weight
- Drug distribution within the blend
- Dissolution after capsule-shell rupture
- Moisture uptake
- Stability of the calcium salt
- Bioequivalence performance
Sodium lauryl sulfate reduction or removal
Sodium lauryl sulfate may support wetting, but its removal could improve excipient-label positioning for patients and purchasers seeking simpler formulations. Alternatives include poloxamers, low levels of surfactant-free wetting systems, particle-size reduction, or improved granulation.
A direct substitution should not be assumed to be equivalent. Fenoprofen calcium dissolution may depend on particle size, wetting, hydrophobic lubrication, and the composition of the capsule fill. Comparative dissolution testing across physiologic pH conditions would be required.
Vegetarian capsule shells
A hydroxypropyl methylcellulose capsule could replace gelatin. This provides a commercial positioning opportunity for vegetarian, religious-compliance, and animal-origin-sensitive markets.
The main technical risks are differences in:
- Capsule-shell moisture content
- Brittleness under low humidity
- Disintegration time
- Compatibility with the fill blend
- Stability during packaging and storage
A switch to HPMC could be valuable in export markets even when it does not create meaningful U.S. exclusivity.
Immediate-release performance optimization
Nalfon is an immediate-release capsule. A reformulation could target faster and more reproducible release through:
- Lower hydrophobic lubricant levels
- Improved wetting
- More uniform particle-size distribution
- Roller compaction or wet granulation
- A disintegrant system with better capsule-plug breakup
- Controlled moisture during blending and encapsulation
The commercial value would come from batch consistency and regulatory differentiation, not from claiming a fundamentally new mechanism.
Sprinkle or easy-swallow presentation
A capsule that can be opened and mixed with a suitable food vehicle could address swallowing difficulty. This opportunity has higher regulatory and stability complexity because the sponsor would need to characterize:
- Dose recovery after opening
- Content uniformity in the food vehicle
- Stability after dispersion
- Palatability
- Drug release after administration
- Labeling instructions
Fenoprofen’s bitter taste and NSAID irritation potential make palatability a material development issue. A sprinkle product would require stronger evidence than a conventional capsule reformulation.
Enteric or delayed-release delivery
An enteric-coated product could be positioned around gastric exposure, but the commercial and regulatory case is weak unless the formulation demonstrates a clinically relevant advantage. Enteric protection does not eliminate systemic NSAID gastrointestinal risks, which arise in part from systemic prostaglandin inhibition.
A delayed-release design also risks slower analgesic onset, variable absorption, and a more demanding bioequivalence program. It is a higher-risk strategy than a conventional immediate-release capsule.
What Nalfon formulation patents protect the product?
No broad, commercially important Nalfon excipient patent estate is apparent from the conventional public product profile. Nalfon is an older small-molecule product, and its principal commercial barrier is generic substitution rather than a modern formulation patent platform.
The relevant intellectual-property categories are:
| IP category |
Relevance to Nalfon |
| Compound patents |
Likely historical and expired for fenoprofen calcium |
| Basic capsule formulation patents |
Likely historical or expired |
| Method-of-use patents |
Possible historical coverage, but limited value if expired |
| Salt or polymorph patents |
Requires a current patent search for live claims |
| Manufacturing patents |
Could affect a specific process, but not necessarily the marketed product |
| Current formulation patents |
No material estate should be assumed without claim-level review |
| Trademark rights |
Nalfon brand rights may remain commercially relevant even without patent exclusivity |
A freedom-to-operate review should search fenoprofen, fenoprofen calcium, Nalfon, capsule formulations, particle-size control, polymorphs, salts, manufacturing processes, and U.S. patents with unexpired claims. Patent expiration cannot be inferred solely from the age of the brand.
When does Nalfon lose exclusivity?
Nalfon’s practical exclusivity has already shifted from branded patent protection to a generic-market structure. FDA-approved generic fenoprofen calcium products can compete if they satisfy applicable ANDA requirements and any listed patent or exclusivity obligations.
For an older product, the relevant commercial questions are:
- Whether any Orange Book-listed patents remain active.
- Whether FDA-listed exclusivity remains.
- Whether an ANDA applicant has submitted a Paragraph IV certification.
- Whether litigation triggered a 30-month stay.
- Whether a settlement agreement restricts generic launch.
- Whether the brand has an authorized generic or supply agreement.
The FDA Orange Book is the controlling public source for current patent listings and exclusivity information.[2] A commercial diligence file should record the NDA number, listed patents, expiration dates, delisting events, and any patent certifications filed by generic applicants.
What is the Orange Book status of Nalfon?
Nalfon should be analyzed through its NDA and current Orange Book entries rather than through brand-level assumptions. The Orange Book identifies approved drug products, reference listed drugs, patents submitted by NDA holders, and applicable exclusivity information.[2]
For a generic developer, the relevant regulatory path is generally an ANDA referencing the applicable fenoprofen calcium reference product. If a listed patent is identified, the applicant must make the appropriate certification under the Hatch-Waxman framework. A Paragraph IV certification can create patent litigation exposure and, in certain circumstances, a 30-month stay of approval.[3]
The commercial significance of any Nalfon patent listing depends on the exact claim scope. A formulation patent covering a specific excipient ratio or release profile may not block a conventional immediate-release capsule using a different composition.
Which companies are challenging Nalfon or competing with fenoprofen?
Competition comes from two groups:
- Generic fenoprofen calcium manufacturers and distributors
- Alternative NSAID suppliers, including manufacturers of ibuprofen, naproxen, ketoprofen, diclofenac, meloxicam, and celecoxib products
Fenoprofen is a niche NSAID. Physicians and payers can substitute across the class based on price, formulary position, dosing convenience, patient response, renal and gastrointestinal risk, cardiovascular profile, and prescribing history.
A generic manufacturer can compete without copying the Nalfon excipient system. The preferred strategy is to establish pharmaceutical equivalence and bioequivalence with an optimized formulation, subject to FDA requirements for the selected reference product.[4]
What commercial opportunities exist for Nalfon reformulation?
Opportunity ranking
| Opportunity |
Technical risk |
Regulatory burden |
Commercial potential |
| Lactose-free capsule |
Low to moderate |
ANDA or formulation-change pathway |
Moderate |
| HPMC vegetarian capsule |
Low to moderate |
ANDA or formulation-change pathway |
Moderate |
| Simplified excipient label |
Moderate |
Bioequivalence and stability work |
Moderate |
| Faster-dissolving immediate-release capsule |
Moderate |
Bioequivalence and CMC package |
Moderate |
| Sprinkle capsule |
High |
Expanded clinical and labeling work |
Moderate to high |
| Enteric-coated capsule |
High |
Stronger clinical justification likely needed |
Uncertain |
| Sustained-release product |
High |
Potential 505(b)(2) pathway |
High but uncertain |
| Combination product |
Very high |
New clinical and regulatory program |
Potentially high |
The most defensible commercial programs are lactose-free, vegetarian-shell, and excipient-minimized capsules. These projects can support private-label, specialty-pharmacy, institutional, and international-market positioning without requiring the clinical investment associated with a new delivery system.
Can a 505(b)(2) product create stronger exclusivity?
A 505(b)(2) application could be relevant if the product introduces a meaningful change from the approved capsule, such as a new dosage form, route, release profile, or clinically supported delivery feature.[5]
Potential 505(b)(2) concepts include:
- A liquid or suspension for patients unable to swallow capsules
- A sprinkle product with validated administration instructions
- A modified-release product
- A fixed-dose combination with another analgesic
- A formulation with a demonstrated reduction in local gastric exposure
The value of a 505(b)(2) program depends on whether the change supports new clinical labeling and statutory exclusivity. A simple excipient substitution that remains therapeutically equivalent is more likely to fit an ANDA or supplement strategy than a 505(b)(2) strategy.
What manufacturing and IP barriers affect Nalfon reformulation?
The main technical barriers are powder flow, content uniformity, dissolution, capsule-shell compatibility, moisture control, and reproducible scale-up. Fenoprofen calcium may require careful control of particle-size distribution and blend segregation because the active ingredient is present at a relatively low fraction of total capsule mass.
The principal IP barriers are narrower:
- Unexpired patents covering fenoprofen calcium forms
- Claims covering particle-size distributions
- Capsule formulations with specific excipient ratios
- Drug-release profiles
- Processes that produce a claimed solid form
- Regulatory exclusivity connected to a new formulation
A design-around should use independently developed excipient ratios, process conditions, and release specifications. Patent clearance should focus on claim scope, not merely patent titles or expired family members.
What litigation and settlement risks apply?
Paragraph IV litigation is possible if the Orange Book contains an unexpired patent that an ANDA applicant certifies as invalid, unenforceable, or not infringed. If no relevant live patent is listed, the main risks shift to ordinary patent infringement, trade-secret disputes, manufacturing contracts, trademark issues, and regulatory delays.
Settlement agreements should be reviewed for:
- Authorized-generic commitments
- Entry dates
- Supply restrictions
- Geographic limits
- Formulation restrictions
- Patent-license terms
- Royalty obligations
No settlement should be assumed to exist without a review of FDA litigation records, court dockets, SEC filings, and the sponsor’s public disclosures.
How does Nalfon compare with other NSAID commercial opportunities?
| Product category |
Differentiation potential |
Generic pressure |
Reformulation opportunity |
| Fenoprofen calcium |
Moderate through presentation and excipients |
High |
Moderate |
| Ibuprofen |
Low for standard tablets; higher for pediatric and liquid products |
Very high |
Moderate |
| Naproxen |
Moderate for delayed-release and suspension products |
High |
Moderate |
| Celecoxib |
Higher because of COX-2 positioning |
High |
Moderate |
| Meloxicam |
Moderate for liquid and low-dose products |
High |
Moderate |
| Diclofenac |
Higher for topical and modified-release forms |
High |
High |
Nalfon has less volume potential than major NSAIDs, but its smaller competitive field can reduce development complexity. The opportunity is strongest where a sponsor can secure a specialty channel, a differentiated label, or a reliable institutional supply position.
What revenue exposure and launch scenarios exist?
Public financial disclosures generally do not provide enough product-level information to isolate Nalfon revenue reliably. The product should therefore be modeled through scenarios rather than assumed brand sales.
| Scenario |
Product concept |
Commercial outcome |
| Base case |
Conventional generic capsule |
Low price, volume-dependent |
| Upside case |
Lactose-free or vegetarian capsule |
Premium in selected channels |
| Specialty case |
Sprinkle or easy-swallow product |
Higher development cost and possible differentiation |
| Platform case |
Modified-release or combination product |
Potential exclusivity, but clinical and regulatory risk |
| Defensive case |
Authorized generic or contract manufacturing |
Lower margin, more predictable supply |
The strongest near-term business case is a differentiated immediate-release capsule with a clean excipient profile, stable supply, and targeted distribution. A modified-release product requires a materially larger investment and should not be justified by brand recognition alone.
Key Takeaways
- Nalfon contains fenoprofen calcium in 200 mg and 300 mg immediate-release capsules.
- The practical market is generic and highly price-sensitive.
- The best excipient opportunities are lactose-free fills, simplified excipient systems, HPMC shells, and improved dissolution consistency.
- A 505(b)(2) strategy is more appropriate for a genuinely new dosage form or clinically supported delivery advantage.
- No biosimilar pathway applies because fenoprofen calcium is a small molecule.
- Current Orange Book listings, Paragraph IV certifications, patent expiration dates, and settlement terms require live regulatory and litigation review.
- Nalfon’s commercial value is more likely to come from niche differentiation and supply reliability than from legacy patent exclusivity.
- A reformulation should be designed around bioequivalence, manufacturability, patient acceptability, and freedom to operate.
FAQs
Is Nalfon still protected by patents?
Nalfon is an older fenoprofen calcium product, and generic competition is the primary market structure. Current protection must be determined from the FDA Orange Book and a live patent-family review.
Can a company launch a lactose-free Nalfon generic?
Potentially. The sponsor would need to select the applicable reference product, develop a pharmaceutically equivalent formulation, demonstrate bioequivalence, satisfy CMC requirements, and address any current listed patents or exclusivity.
Does Nalfon have a pediatric liquid opportunity?
A pediatric liquid could create a differentiated product, but fenoprofen’s indication, taste, dosing requirements, NSAID warnings, and pediatric clinical data requirements would make the program more complex than a capsule reformulation.
Can an HPMC capsule create market exclusivity?
An HPMC shell alone generally provides limited exclusivity. It may support product differentiation, but meaningful statutory exclusivity would depend on the regulatory pathway and the extent of the new product claims.
Is fenoprofen calcium suitable for a sustained-release product?
It may be technically feasible, but the product would require proof that modified release provides a clinically relevant benefit without compromising onset, safety, or bioequivalence. The commercial case is less certain than for a simpler immediate-release reformulation.
References
-
DailyMed. (n.d.). Nalfon-200 and Nalfon-300: Fenoprofen calcium capsule prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). Guidance for industry. https://www.fda.gov/
